癸卯年首场泌尿男生殖系肿瘤的国际大秀——2023年美国临床肿瘤学会（ASCO）泌尿男生殖系肿瘤研讨会（ASCO-GU 2023）将于当地时间2月16~18日在美国旧金山举行。在前列腺癌领域，PARPi＋恩扎卢胺一线治疗mCRPC的TALAPRO-2研究、rucaparib对比化疗或二代AR抑制剂的TRITON3研究等四项研究成果入围口头报告，此外，还有几项值得关注的研究入围快速摘要环节。
Part.1
Oral Abstract Session A: Prostate Cancer
摘要号：LBA17
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
talazoparib（TALA）+恩扎卢胺（ENZA）对比安慰剂（PBO）+ ENZA用于转移性去势抵抗性前列腺癌（mCRPC）患者一线治疗的3期研究。
摘要号：303
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
rucaparib治疗转移性去势抵抗性前列腺癌（mCRPC）：TRITON3研究中rucaparib对比多西他赛或二代AR通路抑制剂的疗效和OS中期分析。
摘要号：33
FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).
FORMULA-509：一项在前列腺根治性切除术后给予挽救性放疗和6个月GnRH激动剂联合或不联合醋酸阿比特龙/泼尼松和阿帕他胺的多中心随机试验。
摘要号：299
Patient-level data meta-analysis of a multi-modal artificial intelligence (MMAI) prognostic biomarker in high-risk prostate cancer: Results from six NRG/RTOG phase III randomized trials.
高危前列腺癌多模态人工智能（MMAI）预后生物标志物的患者水平数据荟萃分析：来自六项NRG/RTOG III期随机试验的结果。
Part.2
Rapid Abstract Session: Prostate Cancer
摘要号：305
Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).
一项采用碘-125近距离放疗、外照射放疗（ERBT）以及长期或短期短期雄激素剥夺治疗局部高危前列腺癌的多中心、随机、三期试验结果（TRIP/TRIGU0907）。
摘要号：19
Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
帕博利珠单抗联合多西他赛治疗转移性去势抵抗性前列腺癌（mCRPC）：随机、双盲、3期KEYNOTE-921研究。
摘要号：20
Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): the peace-1 trial.< />>
醋酸阿比特龙＋泼尼松＋ADT±多西他赛治疗转移性去势敏感性前列腺癌（mCSPC）中老年患者（≥70岁）与年轻患者（＜70岁）的疗效和安全性比较：The PEACE-1试验。
摘要号：LBA21
Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).
酮康唑（keto）、氢化可的松（HC）和镥-177或铟-111标记的抗PSMA抗体J591用于治疗高危非转移性（met）去势抵抗性前列腺癌（M0 CRPC）患者的随机双盲II期研究。
摘要号：170
Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.
Niraparib（NIRA）联合醋酸阿比特龙和泼尼松（AAP）用于治疗携带同源重组修复（HRR）基因的转移性去势抵抗性前列腺癌（mCRPC）患者（pts）：MAGNITUDE第二次中期分析（IA2）。
摘要号：176
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.
首创新药口服先天免疫激活剂BXCL701联合帕博利珠单抗治疗具有小细胞神经内分泌（SCNC）表型的转移性去势抵抗性前列腺癌（mCRPC）患者：一项2a期研究的最终结果。